New employee

September 1, 2021

Akthelia has enlisted Steingrímur Stefánsson in the role of Senior Scientist. Steingrímur (Stenni) finished a Ph.D. Degree in molecular biochemistry from Virginia Commonwealth University in 1990 and has worked in senior roles for various biotech companies in the US since then.

He has extensive experience in protein purification, protein modifications, protein-protein interactions, proteinases, their inhibitors.

He also has a wide experience in cancer cell biology and assay development https://www.researchgate.net/profile/Steingrimur-Stefansson

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

New employee

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

New employee

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis